Table 5 The results of univariate and multivariate Cox regression analyses for assessing 3-year recurrence-free survival in the training cohort

Sex (male)

0.033

2.805 (1.086–7.248)

0.180

1.966 (0.732–5.281)

Age (> 65)

0.189

1.569 (0.801–3.070)

Treatment (surgery plus postoperative adjuvant therapy)

0.136

2.213 (0.779–6.283)

T-stage (T3a/b-4a)

0.578

1.310 (0.506–3.395)

Pathological LNM ( + )

0.027

2.917 (1.129–7.536)

0.308

1.771 (0.591–5.307)

MRI-reported EMVI ( + )

0.001

3.162 (1.589–6.292)

0.010

2.523 (1.247–5.106)

CA199 (> 37)

0.584

1.341 (0.469–3.833)

CEA (> 6)

0.079

1.817 (0.932–3.543)

0.370

1.378 (0.684–2.776)

Tumor length (> 42.5 mm)

0.466

1.283 (0.656–2.508)

Wall thickness (> 12 mm)

0.237

0.669 (0.344–1.302)

LN-irregular border and/or adjacent fat invasion ( + )

0.057

1.908 (0.982–3.709)

0.193

0.531 (0.204–1.377)

LN-chemical shift effect ( + )

0.081

1.816 (0.929–3.555)

0.391

1.603 (0.545–4.716)

LN-heterogeneous intensity ( + )

0.154

1.629 (0.833–3.185)

Intratumoral Radscore (> -0.756)

0.797

1.091 (0.561–2.122)

Intratumoral + peritumoral-MRF Radscore (> -0.930)

0.911

0.963 (0.496–1.869)

Intratumoral + peritumoral 3-mm Radscore (> -0.531)

0.289

1.451 (0.730–2.886)

Clinical-radiomics combined model score based-ENE + (> -0.405)

0.003

3.099 (1.485–6.466)

0.012

2.625 (1.233–5.586)